LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials. Shares of these ...

Biogen joins major drugmakers such as Eli  Lilly, Roche and Merck, who have all announced investments in the U.S. as the ...

Pharma companies' earnings outlook is being obscured by concerns over revived "most-favored-nation" drug pricing rules in the ...

The rising occurrence of dysmenorrhea, along with greater awareness and advancements in diagnosis, is driving substantial growth in the dysmenorrhea ...

Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares ...

The U.K. biopharmaceutical giant’s plans include a proposal for a new drug substance manufacturing center focused on ...

The drugmaker has invested $10 billion in Wake and Durham counties over the past 30 years. Biogen says that figure will increase.

Omega Funds has raised $647 million for the investment shop’s latest round aimed at life sciences companies targeting unmet medical needs. | Omega Funds has raised $647 million for the investment shop ...

Longer treatment duration, not having diabetes, and using semaglutide are among the factors linked to better weight reduction over 12 months.